Global Angiogenesis Therapeutic Agent Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Angiogenesis Therapeutic Agent Market Insights, Forecast to 2034
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
Global Angiogenesis Therapeutic Agent market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Angiogenesis Therapeutic Agent industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Angiogenesis Therapeutic Agent key manufacturers include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Angiogenesis Therapeutic Agent were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Angiogenesis Therapeutic Agent market and estimated to attract more attentions from industry insiders and investors.
Angiogenesis Therapeutic Agent can be divided into Myopic Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy and Macular Degeneration, etc. Myopic Choroidal Neovascularization is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Angiogenesis Therapeutic Agent is widely used in various fields, such as Retail Pharmacies, Online Pharmacies and Hospital Pharmacies,, etc. Retail Pharmacies provides greatest supports to the Angiogenesis Therapeutic Agent industry development. In 2022, global % sales of Angiogenesis Therapeutic Agent went into Retail Pharmacies filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Angiogenesis Therapeutic Agent market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Angiogenesis Therapeutic Agent market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implandata ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika
Segment by Type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Angiogenesis Therapeutic Agent plant distribution, commercial date of Angiogenesis Therapeutic Agent, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Angiogenesis Therapeutic Agent introduction, etc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Angiogenesis Therapeutic Agent
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Angiogenesis Therapeutic Agent market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Angiogenesis Therapeutic Agent industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Angiogenesis Therapeutic Agent key manufacturers include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Angiogenesis Therapeutic Agent were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Angiogenesis Therapeutic Agent market and estimated to attract more attentions from industry insiders and investors.
Angiogenesis Therapeutic Agent can be divided into Myopic Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy and Macular Degeneration, etc. Myopic Choroidal Neovascularization is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Angiogenesis Therapeutic Agent is widely used in various fields, such as Retail Pharmacies, Online Pharmacies and Hospital Pharmacies,, etc. Retail Pharmacies provides greatest supports to the Angiogenesis Therapeutic Agent industry development. In 2022, global % sales of Angiogenesis Therapeutic Agent went into Retail Pharmacies filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Angiogenesis Therapeutic Agent market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Angiogenesis Therapeutic Agent market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implandata ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika
Segment by Type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration
Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Angiogenesis Therapeutic Agent plant distribution, commercial date of Angiogenesis Therapeutic Agent, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Angiogenesis Therapeutic Agent introduction, etc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Angiogenesis Therapeutic Agent
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
